| abstract |
Disclosed is a fusion protein comprising an FGF21 variant and an Fc region, wherein the FGF21 variant comprises the following mutations relative to the full length hFGF21 sequence SEQ ID NO:1: Q55C, R105K, G148C, K150R, P158S, S195A, P199G, and G202A. Also disclosed is the use of the above described fusion protein in the manufacture of a medicament for use in achieving one or more biological activities selected from the group consisting of: lowering blood glucose, lowering insulin levels, lowering triglyceride levels, lowering cholesterol levels, reducing liver lipid levels, reducing liver triglyceride levels, reducing body weight, improving glucose tolerance, and improving insulin sensitivity in a patient. |